TR200101757T2 - Vitronektin reseptör antagonisti farmasötikler - Google Patents

Vitronektin reseptör antagonisti farmasötikler

Info

Publication number
TR200101757T2
TR200101757T2 TR2001/01757T TR200101757T TR200101757T2 TR 200101757 T2 TR200101757 T2 TR 200101757T2 TR 2001/01757 T TR2001/01757 T TR 2001/01757T TR 200101757 T TR200101757 T TR 200101757T TR 200101757 T2 TR200101757 T2 TR 200101757T2
Authority
TR
Turkey
Prior art keywords
useful
present
new compounds
treatment
receptor antagonist
Prior art date
Application number
TR2001/01757T
Other languages
English (en)
Turkish (tr)
Inventor
H. Cheesman Edward
Sworin Michael
Rajopadhyem Milind
Original Assignee
Dupont Pharmaceuticais Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticais Company filed Critical Dupont Pharmaceuticais Company
Publication of TR200101757T2 publication Critical patent/TR200101757T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
TR2001/01757T 1998-12-18 1999-12-17 Vitronektin reseptör antagonisti farmasötikler TR200101757T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11283198P 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
TR200101757T2 true TR200101757T2 (tr) 2001-12-21

Family

ID=22346057

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01757T TR200101757T2 (tr) 1998-12-18 1999-12-17 Vitronektin reseptör antagonisti farmasötikler

Country Status (6)

Country Link
US (2) US6558649B1 (US06818201-20041116-C00086.png)
EP (1) EP1140864A2 (US06818201-20041116-C00086.png)
AU (1) AU2371400A (US06818201-20041116-C00086.png)
CA (1) CA2349333A1 (US06818201-20041116-C00086.png)
TR (1) TR200101757T2 (US06818201-20041116-C00086.png)
WO (1) WO2000035887A2 (US06818201-20041116-C00086.png)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
WO2001097861A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2002326494A1 (en) * 2001-08-01 2003-02-17 Smithkline Beecham Corporation Products and drug delivery vehicles
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
WO2003062198A1 (en) 2002-01-24 2003-07-31 Barnes Jewish Hospital Integrin targeted imaging agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
ATE449614T1 (de) * 2003-05-12 2009-12-15 Lantheus Medical Imaging Inc Vitronectin rezeptorantagonisten und ihre verwendung als radiopharmazeutika
US20070104645A1 (en) * 2003-09-30 2007-05-10 Garlich Joseph R Chelate based scaffolds in tumor targeting
JP2008502726A (ja) 2004-06-09 2008-01-31 ケレオス インコーポレーティッド キレートモノアミドの親油性誘導体
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
KR20090014164A (ko) * 2006-04-19 2009-02-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
BRPI0915368B1 (pt) 2008-07-03 2019-01-15 Monsanto Technology Llc composição compreendendo glifosato ou um sal ou um ester de glifosato e método de controlar crescimento de planta
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
FR2977892B1 (fr) 2011-07-13 2013-07-26 Servier Lab Nouveaux agents d'imagerie, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4248802A (en) * 1975-06-20 1981-02-03 Rhone-Poulenc Industries Catalytic hydroformylation of olefins
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4859777A (en) 1981-07-01 1989-08-22 Eastman Kodak Company Terpyridine chelating agents
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
DE3360633D1 (en) 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4452774A (en) 1982-04-30 1984-06-05 President And Fellows Of Harvard College Isonitrile radionuclide complexes for labelling and imaging agents
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
WO1987002893A1 (en) 1985-11-18 1987-05-21 Board Of Regents, The University Of Texas System Polychelating agents for image and spectral enhancement (and spectral shift)
CA1305160C (en) 1985-12-23 1992-07-14 Paul Louis Bergstein Ether isonitriles and radiolabeled complexes thereof
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US5567411A (en) 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
US5252317A (en) 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5064956A (en) 1987-06-24 1991-11-12 The Dow Chemical Company Process for preparing mono-n-alkylated polyazamacrocycles
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
CA2002860A1 (en) 1988-11-14 1990-05-14 Michael A. Gimbrone Antibodies specific for elam-1 and the use thereof
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
ATE174223T1 (de) 1989-04-10 1998-12-15 Oncogen Verwendung von oncostatin m zur suppression von mhc antigenen
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5395609A (en) 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
WO1991001144A1 (en) 1989-07-20 1991-02-07 Sandoz Ltd Labeled polypeptide derivatives
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
GB9006977D0 (en) 1990-03-28 1990-05-23 Nycomed As Compositions
TW212184B (US06818201-20041116-C00086.png) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
IN172208B (US06818201-20041116-C00086.png) 1990-04-02 1993-05-01 Sint Sa
US5382654A (en) 1992-02-05 1995-01-17 Mallinckrodt Medical, Inc. Radiolabelled peptide compounds
SK77393A3 (en) 1991-01-24 1994-12-07 Cytel Corp Pharmaceutical mixture for treatment of illnesses by inhibition of intercellular adhesion by elam-1
US5504064A (en) 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH06507639A (ja) 1991-05-03 1994-09-01 ザ ロックフェラー ユニバーシティ セレクチンとｂ百日咳毒素の間のアミノ酸シーケンスの相同性−それから誘導されるペプチド、それに対する抗体、薬剤組成物
WO1993008210A1 (en) 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
GB9209641D0 (en) 1992-05-02 1992-06-17 Johnson Matthey Plc Improvements in radiolabelling
WO1994005328A1 (en) 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
DE4301871A1 (de) 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5760191A (en) 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US5744120A (en) * 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
CA2158249A1 (en) 1993-03-31 1994-10-13 James W. Brodack Radiopharmaceutical formulations having non-stannous reductants
DE4311023C2 (de) 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
EP0710228B1 (en) 1993-07-19 1998-01-21 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n 3?s configuration
US5417959A (en) 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
MA23420A1 (fr) 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
PL318199A1 (en) 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
HU220347B (hu) 1994-07-11 2001-12-28 Board Of Regents The University Of Texas System Készítmény az érrendszer specifikus koagulálásához
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US5520904A (en) 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
SE515621C2 (sv) * 1995-05-08 2001-09-10 Ericsson Telefon Ab L M Förfarande vid lägesbestämning
US5801228A (en) 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
GB9511989D0 (en) 1995-06-13 1995-08-09 Glaxo Group Ltd Chemical compounds
CZ293323B6 (cs) 1995-08-30 2004-04-14 G. D. Searle & Co. Meta-guanidinové, močovinové, thiomočovinové nebo azacyklické deriváty aminobenzoové kyseliny jako antagonisty integrinů
DE19536785A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
DE19536781A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
DE69628731T3 (de) 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
EP0863885A2 (en) 1995-11-14 1998-09-16 The Du Pont Merck Pharmaceutical Company Novel macrocyclic compounds as metalloprotease inhibitors
EP0939757A1 (en) 1995-12-22 1999-09-08 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
US5879659A (en) * 1996-03-13 1999-03-09 Dupont Pharmaceuticals Company Ternary radiopharmaceutical complexes
US5804161A (en) 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
ZA978758B (en) 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4753997A (en) 1996-10-16 1998-05-11 Burnham Institute, The Magnetic resonance imaging of thrombi
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
WO1998018497A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
EP1007051A4 (en) 1997-08-04 2001-08-29 Smithkline Beecham Corp INTEGRIN RECEPTOR ANTAGONISTS
EP1015884B1 (en) 1997-09-10 2008-08-06 The Burnham Institute Methods of identifying molecules that home to angiogenic vasculature in tumors
CA2320339A1 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
JP2002521450A (ja) 1998-07-29 2002-07-16 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
WO2000046215A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6254852B1 (en) * 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents

Also Published As

Publication number Publication date
AU2371400A (en) 2000-07-03
WO2000035887A2 (en) 2000-06-22
EP1140864A2 (en) 2001-10-10
US6558649B1 (en) 2003-05-06
WO2000035887A3 (en) 2000-11-16
US20030143235A1 (en) 2003-07-31
US6818201B2 (en) 2004-11-16
CA2349333A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
TR200101757T2 (tr) Vitronektin reseptör antagonisti farmasötikler
WO2000035492A3 (en) Vitronectin receptor antagonist pharmaceuticals
CY1107746T1 (el) Ανταγωνιστες του αλφα v ιντεγκρινικου υποδοχεα
DE60036945D1 (de) Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
EP0253310A3 (en) Angiotensin ii receptor blocking imidazoles
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
NO923032D0 (no) Aryl-, amid-, imid- og karbamatpyridinantagonister for blodplateaktiverende faktor
ATE234812T1 (de) Integrin antagonisten
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
AU2371500A (en) Vitronectin receptor antagonist pharmaceuticals
HUP9700660A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása a prosztata jóindulatú hyperpláziájának megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
IT1310244B1 (it) Sistema e macchina per l'apertura automatizzata di cassetteripieghevoli.
MXPA01010186A (es) Composiciones y metodos para el tratamiento y diagnostico de cancer de mama.
TR200100363T2 (tr) Vitronektin reseptör antagonistleri.
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
DK348087A (da) 4-nitrogensubstituerede isoquinolinol-forbindelser samt fremgangsmaade til fremstilling deraf
Reingold Interpreting dissociations: The issue of task comparability.
IT1320619B1 (it) Procedimento per il rilevamento multiplo di segnali optoelettronici edispositivo per l'effettuazione del procedimento.
IT1317437B1 (it) Macchina per la lavorazione e/o produzione di oggetti
DE602004009097D1 (de) 1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivative
FR2799102B1 (fr) Vetement d'une seule piece, unisexe, de type combinaison, pour personne malade ou incontinente, alitee ou non